Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News .
The deal is designed to marry UNP’s macrocyclic peptide discovery platform with Argenx’s immunology innovation capabilities to broaden the buyer’s ability to develop oral or long-acting treatments for serious immune-mediated diseases. The post Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News .
This is a summary of the story. Read the full article at GEN — Genetic Engineering & Biotechnology News ↗